Detalhe da pesquisa
1.
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.
N Engl J Med
; 385(25): 2348-2360, 2021 12 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-34587382
2.
Protein dose-sparing effect of AS01B adjuvant in a randomized preventive HIV vaccine trial of ALVAC-HIV (vCP2438) and adjuvanted bivalent subtype C gp120.
J Infect Dis
; 2023 Oct 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37795976
3.
Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials.
PLoS Pathog
; 17(11): e1010016, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34843602
4.
Time to Viral Rebound After Interruption of Modern Antiretroviral Therapies.
Clin Infect Dis
; 74(5): 865-870, 2022 03 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34117753
5.
Maintenance of Viral Suppression in Human Immunodeficiency Virus Controllers Despite Waning T-Cell Responses During Antiretroviral Therapy.
J Infect Dis
; 222(11): 1837-1842, 2020 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32496516
6.
Antiretroviral Therapy Reduces T-cell Activation and Immune Exhaustion Markers in Human Immunodeficiency Virus Controllers.
Clin Infect Dis
; 70(8): 1636-1642, 2020 04 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31131858
7.
The Emperor's New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE).
Clin Infect Dis
; 70(8): 1536-1545, 2020 04 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31157370
8.
Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial.
J Virol
; 93(21)2019 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31434737
9.
Reducing the African American HIV Disease Burden in the Deep South: Addressing the Role of Faith and Spirituality.
AIDS Behav
; 23(Suppl 3): 319-330, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31444712
10.
Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial.
J Infect Dis
; 217(8): 1280-1288, 2018 03 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29325070
11.
Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy.
Clin Infect Dis
; 67(11): 1712-1719, 2018 11 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-29590326
12.
Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial.
J Infect Dis
; 215(9): 1376-1385, 2017 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28199679
13.
Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083.
J Infect Dis
; 213(4): 541-50, 2016 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26475930
14.
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.
N Engl J Med
; 369(22): 2083-92, 2013 Nov 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-24099601
15.
Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.
J Infect Dis
; 210(1): 99-110, 2014 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24403557
16.
Theoretical model of critical issues in informed consent in HIV vaccine trials.
AIDS Care
; 26(11): 1452-60, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24865892
17.
Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery.
J Infect Dis
; 208(5): 818-29, 2013 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23840043
18.
Predictors of HIV rebound differ by timing of antiretroviral therapy initiation.
JCI Insight
; 9(3)2024 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38329130
19.
Polytopic fractional delivery of an HIV vaccine alters cellular responses and results in increased epitope breadth in a phase 1 randomized trial.
EBioMedicine
; 100: 104987, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38306894
20.
Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial.
Lancet HIV
; 11(5): e285-e299, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38692824